Novocure Stock News

Tumor-treating field devices from Novocure employ electric fields to prevent cancer cell multiplication. Its primary market is presently treating glioblastoma multiforme, the most prevalent type of brain cancer, but it also targets other solid tumors, including lung cancer. Oncology has historically concentrated on three approaches to cancer treatment: surgery,

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure has signed an agreement to acquire and construct an office building at 64 Vaughan Mall, in the heart of downtown Portsmouth, New Hampshire.

NovoCure Limited (NASDAQ:NVCR) shares gapped down prior to trading on Monday . The stock had previously closed at $91.37, but opened at $82.20. NovoCure shares last traded at $80.23, with a volume of 1,877 shares changing hands. NVCR has been the topic of a number of recent analyst reports. Piper Sandler dropped their price objective []

Paragon 28 (NYSE:FNA) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Earnings and Valuation This table compares Paragon 28 and NovoCures top-line revenue, earnings per share and valuation. []

Paragon 28 (NYSE:FNA) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Earnings and Valuation This table compares Paragon 28 and NovoCures top-line revenue, earnings per share and valuation. []

This year's big pullbacks are more the result of a raucous 2020, and less an indictment of these companies' prospects.

This year's big pullbacks are more the result of a raucous 2020, and less an indictment of these companies' prospects.

Equities research analysts expect NovoCure Limited (NASDAQ:NVCR) to report earnings of ($0.10) per share for the current fiscal quarter, according to Zacks. Five analysts have made estimates for NovoCures earnings, with estimates ranging from ($0.14) to ($0.02). NovoCure posted earnings per share of $0.04 during the same quarter last year, which would suggest a negative []

NovoCure stock is way down and attracting bargain shoppers.

NovoCure stock is way down and attracting bargain shoppers.

Even a good year for stocks has its share of high-flyers that have turned into losers — or buying opportunities.

NVCR has an approved product targeting 3 indications, from which it generates revenue.